<DOC>
	<DOC>NCT01511887</DOC>
	<brief_summary>The aim of current study is to evaluate the efficacy and safety of oral Ibuprofen in term 20-28 days old newborn referred to Bandarabbas children' hospital in 2011.</brief_summary>
	<brief_title>Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA)</brief_title>
	<detailed_description>Patent Ductus Arteriosus (PDA) accounts for about 10% of Congenital Heart Disease. Surgical treatment in PDA is associated with higher rate of complication than pharmacologic treatment. Efficacy of Ibuprofen is shown in preterm and low birth weights newborn with PDA. Studies in term neonates after the first days of birth are rare. The aim of current study is to evaluate the efficacy and safety of oral Ibuprofen in term 20-28 days old newborn referred to Bandarabbas children' hospital in 2011.</detailed_description>
	<mesh_term>Ductus Arteriosus, Patent</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Term newborn (37 weeks of gestation or more) Age between 2028 days confirmed diagnosis of PDA by echocardiography by pediatric cardiologist Asphyxia Hemorrhage Platelet count &lt; 150000 renal or gastrointestinal malformations associated congenital heart disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>28 Days</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Patent Ductus Arteriosus</keyword>
	<keyword>PDA</keyword>
	<keyword>Term newborns</keyword>
	<keyword>Ibuprofen</keyword>
</DOC>